Toronto Stock Exchange Symbol: MS
EDMONTON, March 18 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis ("MS"), today announced financial and operational results for the year ended December 31, 2007.
"We continue to focus on the worldwide development of MBP8298, our proprietary synthetic peptide drug for the treatment of multiple sclerosis, which is being evaluated in several late-stage trials in the U.S., Canada and across Europe," said Kevin Giese, President and CEO of BioMS Medical. "The magnitude of the partnership we formed with Lilly at the end of 2007 for the global rights to MBP8298 underscores the enormous potential of our drug and is a validation of all the years of hard work performed by our team."
Currently, BioMS is conducting three clinical trials and one open-label
follow-on trial for MBP8298:
- MAESTRO-01: A pivotal phase II/III trial in Canada and Western Europe
evaluating MBP8298 for the treatment of secondary progressive MS
("SPMS"). On January 22, 2007, BioMS announced that the trial had
completed full recruitment of 611 patients at 47 trial sites in
10 countries. Patients are administered either MBP8298 or placebo
every six months for a period of two years. To date, there have been
eight positive safety reviews from the Data Safety Monitoring Board
("DSMB"). An interim analysis on the first 200 patients is expected
- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal
trial. Eligible patients who have successfully completed the blinded,
placebo controlled MAESTRO-01 trial may choose to receive MBP8298 on
an un-blinded basis.
- MAESTRO-03: A U.S. pivotal phase III trial evaluating MBP8298 for the
treatment of SPMS. Enrollment for the randomized, double-blind s
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved